-
Awarded14/01/2026
-
Today15/05/2026
Utilities
- indicates text translated automatically in your browsing language
Acquisition of multiplex-NhO reagents for bacterial pneumonia and arthritis diagnostics
The acquisition is based on NordLab's strategic goal of speeding up microbiological diagnostics and procedure, introducing new NhO studies. The introduction of an arthritis panel and a bacterial pneumonia panel for intensive care patients will speed up the initial result by 1-2 days compared to the current method. This, in turn, speeds up the decision-making process and improves the patient's prognosis. NordLab published a request for information in the Hilma service on 22.8.2025. On the basis of the responses to the request for information, it could be concluded that there are no other fully automatic devices of bioMérieux Suomi Oy on the market in Finland for the isolation, amplification and detection of nucleic acid. NordLab has signed an agreement with bioMérieux Suomi Oy.
Type: price
Description: Reagenssien hinta
Weight (percentage, exact): 100
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.